ClinicalTrials.gg
Not yet recruitingNCT06754865XYP-202401Updated Jan 1, 2025

Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data

An observational study in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-01-01.

Sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,140
Sex
All
01

Study summary

The primary objective is to evaluate the effect of Xiyanping injection on the treatment course of intravenous antibiotics for acute exacerbation of chronic obstructive pulmonary disease based on real-world clinical data, and to provide guidance and basis for the clinical application of Xiyanping injection combined with antibiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease.The secondary objectives is to evaluate the effect of Xiyanping injection on the indicators of acute exacerbation of inflammation and symptom improvement of chronic obstructive pulmonary disease.

02

Conditions studied

  • Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Keywords

  • Acute exacerbation of chronic obstructive pulmonary disease
  • Xiyanping injection
03

In context

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

This study's planned enrollment of 1,140 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Jiangxi Qingfeng Pharmaceutical Co. Ltd. is the lead sponsor of 32 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute exacerbation of chronic obstructive pulmonary disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Discharged with ;
  2. Hospitalized patients with COPD or AECOPD combined with lower respiratory tract infection;
  3. The treatment course of Xiyanping injection in the exposed group was ≥3 days, and the non-exposed group did not use Xiyanping injection;
  4. Study patients with complete medical records.

Exclusion criteria

Exclusion Criteria:

  1. Researchers believe that multiple proprietary Chinese medicines with the same or similar functions (such as Tanreqing injection, Reduning injection, Yanhuning injection, etc.) have been used at the same time during treatment, resulting in no assessment of efficacy or safety;
  2. Patients with viral pneumonia or other systemic infection (such as urinary tract infection);
  3. Patients who do not use intravenous antibiotics;
  4. Refuse the case to be used by researchers.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,140 participants (estimated)
Patient registry
No

Groups and cohorts

  • Exposure group

    Xiyanping injection + Antimicrobial agents treatment

    Drug: Xiyanping injection+ antibiotic

  • Non-exposure group

    Antimicrobial agents treatment

    Drug: Antibiotic

Interventions

  • DrugXiyanping injection+ antibiotic

    Xiyanping injection+ antibiotic

  • DrugAntibiotic

    Antibiotic

06

What researchers measure

Primary outcomes

  1. Course of intravenous antibiotics

    Duration of intravenous antibiotic use

    Time frame: baseline, at 3(±1), 7(±1), and 10 days during medication

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2024; primary completion for Nov 2025, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2024
First posted
Jan 1, 2025
StartEst.
Dec 2024
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Jan 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06754865
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Dec 2024 (estimated)
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Jan 1, 2025

Study contacts

Xiyuan Hospital of China Academy of Chinese Medical Sciences
Contact
010-62835646

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion